Topical product formulations containing strontium for reducing skin irritation

Abstract

Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical formulation vehicle, and methods of using these formulations to inhibit skin irritation, are disclosed.

1 - 65 . (canceled) 
     
     
         66 . A composition for topical application to and for inhibiting skin irritation in an animal subject comprising
 (a) an irritant ingredient contained in an amount capable of inducing skin irritation in the subject,   (b) an anti-irritant amount of aqueous-soluble divalent strontium cation, and   (c) a topical vehicle.   
     
     
         67 . The composition of  claim 66 , wherein the composition is in the form of a solid, liquid, suspension, semisolid, powder, or a finely dispersed liquid. 
     
     
         68 . The composition of  claim 67 , wherein the composition in the form of a solid, liquid, suspension, semisolid, powder, or a finely dispersed liquid is in a form selected from: creams, lotions, moisturizers, sprays, exfoliants, skin cell renewal agents, fragrances, perfumes, colognes, deodorants, shaving creams, shaving bracers, aftershaves, hair removal products, depilatory products, skin cleansers, toners, astringents, pre-moistened wipes or washcloths, tanning lotions, sunscreens, bath products, eye lotions, makeup removers, foot care products, skin colorants, foundations, blushes, rouges, eye shadows, eye liners, lip colors, mascaras, lip balms, lip sticks, lozenges, mouthwashes, hair care and treatment products, baby lotions, baby oils, baby shampoos, baby powders, baby wet wipes, feminine hygiene products, skin peels, and facial peels. 
     
     
         69 . The composition of  claim 66 , wherein the irritant ingredient is selected from the group consisting of carboxylic acids, keto acids, α-hydroxy acids, β-hydroxy acids, retinoids, peroxides, organic alcohols, and mixtures thereof 
     
     
         70 . The composition of  claim 66 , wherein the amount of aqueous-soluble divalent strontium cation is at a concentration ranging from about 10 mM to about 3,000 mM. 
     
     
         71 . The composition of  claim 66 , wherein the amount of aqueous-soluble divalent strontium cation is at a concentration of at least 5 mM. 
     
     
         72 . The composition of  claim 66 , wherein the amount of aqueous-soluble divalent strontium cation is at a concentration of at least 10 mM. 
     
     
         73 . The composition of  claim 66 , wherein the amount of aqueous-soluble divalent strontium cation is at a concentration of at least 50 mM. 
     
     
         74 . The composition of  claim 66 , wherein the inhibition of skin irritation represents an average reduction in one or more of sting, burn and itch in the human population susceptible to the skin irritation upon topical application of the composition, as compared to the level of irritation induced in the population upon topical application of a control formulation containing the irritant ingredient in a vehicle without the strontium cation. 
     
     
         75 . The composition of  claim 66 , wherein the irritant ingredient comprises an ingredient selected from the group consisting of benzoyl peroxide, tretinoin, retinol, retinal, 1-pyrrolidone-5-carboxylic acid, capryloyl salicylic acid, α-hydroxy decanoic acid, α-hydroxy octanoic acid, gluconolactone, methoxypropyl gluconamide, oxalic acid, malic acid, tartaric acid, mandelic acid, benzylic acid, gluconic acid, pyruvic acid, and phenol. 
     
     
         76 . The composition of  claim 66 , wherein the pH of the composition is in the range of 1 to 6. 
     
     
         77 . The composition of  claim 66 , wherein the composition is selected from the group consisting of antibiotic, analgesic, contraceptive, anti-acne, and anti-dandruff, exfoliant, depilatory, skin cell renewal, antiperspirant, antihistamine, anti-inflammatory, skin protective, insect repellent, and sunscreen products. 
     
     
         78 . The composition of  claim 66 , further comprising at least one second anti-irritant agent. 
     
     
         79 . The composition of  claim 78 , wherein the second agent is selected from the group consisting of potassium channel mediating, regulating or blocking agents, calcium channel blocking or regulatory agents, sodium channel blocking agents, steroids, non-steroidal anti-inflammatory agents, aloe vera, chamomile, α-bisabolol, cola nitida extract, green tea extract, tea tree oil, licorice extract, allantoin, urea, caffeine and other xanthines, glycyrrhizic acid, benzoyl peroxide, tretinoin, retinol, retinal, 1-pyrrolidone-5-carboxylic acid, capryloyl salicylic acid, α-hydroxy decanoic acid, α-hydroxy octanoic acid, gluconolactone, methoxypropyl gluconamide, oxalic acid, malic acid, tartaric acid, mandelic acid, benzylic acid, gluconic acid, pyruvic acid and phenol. 
     
     
         80 . A topical formulation for reducing skin irritation in animals comprising:
 a non-strontium active ingredient for effecting primary activity of the topical formulation;   a skin irritation reducing salt comprising aqueous-soluble divalent strontium cation; and   a suitable topical formulation vehicle.   
     
     
         81 . The formulation of  claim 80 , comprising about 0.5% by weight to about 14% by weight of the total formulation of the aqueous-soluble divalent strontium cation. 
     
     
         82 . The formulation of  claim 80 , comprising the aqueous-soluble divalent strontium cation at a concentration ranging from about 10 mM to about 3,000 mM. 
     
     
         83 . The formulation of  claim 80 , wherein salt in the formulation consists essentially of aqueous-soluble divalent strontium cation and one or more counteranions. 
     
     
         84 . A topical formulation for reducing skin irritation in animals comprising:
 (a) a salt comprising aqueous-soluble divalent strontium cation in an amount of about 0.5% by weight to about 14% by weight of the total formulation,   (b) an irritant ingredient, and   (c) a suitable topical formulation vehicle, wherein the formulation vehicle comprises at least one ingredient selected from emollients, moisturizers, fragrances, dyes, and pigments.   
     
     
         85 . A topical formulation for reducing skin irritation in animals comprising:
 a skin irritation reducing salt comprising aqueous-soluble divalent strontium cation; and   a suitable topical formulation vehicle.   
     
     
         86 . The formulation of  claim 85 , wherein the skin irritation reducing salt is present at a pharmaceutically effective concentration to reduce skin irritation.